This review concluded that cyclosporin is consistently effective in treating atopic eczema refractory to topical treatment, and is recommended as the first option for these patients. There was insufficient evidence available for other potential treatments. This was a well-conducted review and the conclusions are likely to be reliable.
Participants included in the review
Studies of patients with severe atopic eczema who did not respond adequately to topical treatments were eligible for inclusion. Where reported, participants were aged from 1 to 18 years in the studies of children, 17 to 73 years in the studies of adults, and 2 to 65 years in the studies of both adults and children.
Outcomes assessed in the review
No inclusion criteria were stated in relation to the outcomes. The primary outcome was change in clinical severity of eczema, in relation to the intensity and extent of skin lesions that were investigator-rated. The other outcomes evaluated were serious adverse events and withdrawals due to adverse events.
How were decisions on the relevance of primary studies made?
Two independent reviewers screened studies for inclusion; any disagreements were resolved by discussion.
Assessment of study quality
Study quality was evaluated in terms of appropriate case definition, the use of validated outcomes, follow-up rates, the use of intention-to-treat analysis, and the adequacy of randomisation, allocation concealment and blinding. The number of reviewers undertaking the validity assessment was not stated, but the assessment seems to have been conducted during the data extraction.
Data extraction
Two independent reviewers extracted the data using a standardised data extraction form; any disagreements were resolved by discussion. The change from baseline in mean objective clinical severity was calculated. The mean relative change in clinical severity was extracted or calculated using absolute scores at baseline and during treatment. Data were estimated from figures or graphs where necessary, and the distribution of relative individual responses abstracted if means were not reported. 
Methods of synthesis
How were the studies combined?
The authors compared RCTs with uncontrolled studies by using the results of the treatment arm only, and only the first stage of RCTs with a crossover design. The study results were combined in a narrative.
How were differences between studies investigated?
Differences between the studies were discussed in the text and study details tabulated.
Results of the review
Twenty-seven studies (n=979) were included in the review. The study designs included were double-blind (n=560), evaluator blind (n=10) Of the 27 studies included, nine had follow-up of less than 80%, with three of these not using an intention-to-treat analysis, 11 RCTs did not report on randomisation concealment, and blinding was deemed inadequate in 9 studies, of which three were RCTs.
Effectiveness.
Cyclosporin A: 11 studies reported a decrease in disease activity with cyclosporine, with superiority over placebo in all 6 RCTs.
Systemic glucocorticosteroids: 2 RCTs in children reported short-term decreases in severity of 22% and 39% after treatment with beclomethasone diproprionate and flunisolide, respectively.
Interferon gamma: 2 poor-quality RCTs reported interferon as superior to placebo in children and adults. One uncontrolled study reported a 30% decrease in the intensity of lesions, while another uncontrolled study reported low response rates.
Intravenous immunoglobulin: 3 small studies reported limited responses to immunoglobulin.
Mycophenolate mofetile: 2 small uncontrolled studies reported short-term decreases in severity of 55% and 68% after 8 and 12 weeks' treatment, respectively.
Azathioprine: one double-blind RCT reported a 27% decrease in disease activity after 12 weeks.
Infliximab: one small uncontrolled study reported a benefit of 50% or more in 2 out of 9 patients.
Chinese herbal medicines: 3 double-blind RCTs reported conflicting results, with 2 poor-quality studies reporting beneficial results and the third study reporting no difference between treatment and placebo.
Adverse events.
Most studies either did not report on serious adverse events, or reported that no serious adverse events occurred. Reported adverse events included abdominal pain, herpes simplex infection, acute cholecystitis, hypertension, haematurea, increased serum creatinine, serum sickle-like illness and serious infusion reaction. The proportion of patients withdrawing due to adverse events ranged from 0 to 10%.
